AGIO Agios Pharmaceuticals Inc Return on Sales by Gross Profit

Official company branding of Agios (AGIO)

Adjusted gross margin demonstrates business efficiency, with the metric holding at 90.00. Agios Pharmaceuticals (AGIO) dominates the treatment of rare anemias due to low demand elasticity and innovations in cellular metabolism. Growth is driven by the expanded application of Pyrukynd and licensing payments for vorasidenib. Stable cash flow and royalties from oncology drugs fully cover the company's capital expenditures.

Agios Pharmaceuticals (AGIO): Gross Margin from 07/04/2022 to 11/20/2026

Financial and market metric breakdowns for agios.com (AGIO)

- current quotes and average value forecast:
Basic company analysis:AGIO Agios
Original product of Agios Pharmaceuticals

Amidst the restructuring of Agios Pharmaceuticals (AGIO) following the spin-off of its oncology division, the gross margin chart reflects the efficiency of cost management for the production of rare disease treatments. This indicator measures the portion of revenue remaining after direct production costs, allowing investors to assess the business's pricing power and its ability to generate profit despite a highly concentrated portfolio.